Adial Pharmaceuticals, Inc. (NASDAQ:ADIL – Get Free Report) was the target of a large drop in short interest during the month of October. As of October 15th, there was short interest totalling 51,200 shares, a drop of 34.2% from the September 30th total of 77,800 shares. Currently, 0.8% of the shares of the company are short sold. Based on an average daily volume of 253,200 shares, the short-interest ratio is presently 0.2 days.
Adial Pharmaceuticals Price Performance
Shares of Adial Pharmaceuticals stock opened at $1.10 on Monday. The firm has a 50-day moving average of $1.02 and a 200-day moving average of $1.23. Adial Pharmaceuticals has a 52-week low of $0.77 and a 52-week high of $4.17.
Adial Pharmaceuticals (NASDAQ:ADIL – Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.20). As a group, equities analysts forecast that Adial Pharmaceuticals will post -1.62 earnings per share for the current year.
Institutional Investors Weigh In On Adial Pharmaceuticals
About Adial Pharmaceuticals
Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.
Recommended Stories
- Five stocks we like better than Adial Pharmaceuticals
- Insider Trades May Not Tell You What You Think
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- Investing in Construction Stocks
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Adial Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adial Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.